HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

AbstractCONTEXT:
Because T-cell interactions are involved in the pathophysiology of psoriasis, therapy with a T-cell modulator may have beneficial effects on psoriasis severity and health-related quality of life (HRQL).
OBJECTIVE:
To assess the efficacy and safety of efalizumab, a T-cell modulator, in patients with plaque psoriasis.
DESIGN, SETTING, AND PATIENTS:
Phase 3 randomized, double-blind, parallel-group, placebo-controlled trial involving 556 adult patients with stable, moderate to severe plaque psoriasis and conducted at 30 study centers in the United States and Canada between January and July 2002.
INTERVENTIONS:
Patients were randomly assigned in a 2:1 ratio to receive 12 weekly doses of subcutaneous efalizumab, 1 mg/kg (n = 369), or placebo equivalent (n = 187).
MAIN OUTCOME MEASURES:
At least 75% improvement on the Psoriasis Area and Severity Index (PASI-75); improvement on the overall Dermatology Life Quality Index (DLQI), Itching Visual Analog Scale (VAS), and Psoriasis Symptom Assessment (PSA) at week 12 vs baseline.
RESULTS:
Efalizumab-treated patients experienced significantly greater improvement on all end points than placebo-treated patients. Twenty-seven percent of efalizumab-treated patients achieved PASI-75 vs 4% of the placebo group ( P<.001). Efalizumab-treated patients exhibited significantly greater mean percentage improvement than placebo-treated patients on the overall DLQI (47% vs 14%; P<.001), Itching VAS (38% vs -0.2%; P<.001), and PSA frequency and severity subscales (48% vs 18% and 47% vs 17%, respectively; P<.001 for both) at the first assessment point. Efalizumab was safe and well tolerated, with primarily mild to moderate adverse events.
CONCLUSION:
In this 12-week study, efalizumab resulted in significant improvements in clinical end points, including physician-assessed and dermatology-specific patient-reported HRQL measures, in patients with moderate to severe plaque psoriasis.
AuthorsKenneth B Gordon, Kim A Papp, Tiffani K Hamilton, Patricia A Walicke, Wolfgang Dummer, Nicole Li, Brian W Bresnahan, Alan Menter, Efalizumab Study Group
JournalJAMA (JAMA) Vol. 290 Issue 23 Pg. 3073-80 (Dec 17 2003) ISSN: 1538-3598 [Electronic] United States
PMID14679270 (Publication Type: Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CD11 Antigens
  • Dermatologic Agents
  • efalizumab
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • CD11 Antigens (immunology)
  • Dermatologic Agents (adverse effects, therapeutic use)
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Psoriasis (drug therapy, immunology)
  • Quality of Life
  • Severity of Illness Index
  • T-Lymphocytes (immunology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: